Medicare Pilot Program to Utilize AI for Pre-Authorization

The Trump administration is set to initiate a program next year aimed at assessing how artificial intelligence can help save costs by denying certain Medicare services. This initiative reflects an approach similar to that of private insurance companies.

The pilot program intends to cut down on what it considers “low-value” services and will expand a contentious process known as pre-authorization. This requires patients or healthcare professionals to obtain approval from insurance providers before proceeding with specific treatments, tests, and prescriptions. Impacting Medicare patients as well as the healthcare providers serving them, this program will start on January 1st and will run until 2031 in states including Arizona, Ohio, Oklahoma, New Jersey, Texas, and Washington.

It has garnered mixed reactions from politicians and experts. The traditional Medicare model, primarily covering those over 65 or with disabilities, has typically avoided such pre-approval processes, unlike private insurance—especially Medicare Advantage plans.

The announcement of this pilot was made in late June, shortly after the administration revealed its voluntary efforts to minimize advance approvals, which critics, including Dr. Mehmet Oz from the Centers for Medicare and Medicaid Services, claim “severely delays” care.

Dr. Oz expressed concerns about the potential erosion of public trust in the healthcare system, stating, “It’s something that cannot be tolerated by this administration.”

Nonetheless, some critics, such as Dr. Vinay Rathi, a physician and policy researcher, have pointed out seeming contradictions in the administration’s stance. He remarked that the federal government is drawing from private insurance methods for savings while simultaneously pushing back on policies that could hamper patient care.

Representative Susan Delbene voiced similar concerns, suggesting that the administration is sending mixed signals, which is troubling.

Patients, healthcare professionals, and lawmakers have also expressed discontent, fearing that such delays could obstruct timely access to necessary care, potentially leading to worsening health outcomes. Representative Greg Murphy, a urologist from North Carolina, criticized the practice as a way for insurance companies to minimize payouts at the expense of patient care.

Insurance companies maintain that prior authorization is essential in curbing fraud and unnecessary expenses while claiming it protects patients. However, dissatisfaction over denials has made headlines, leading to broader public frustration with these practices—over 70% of survey respondents viewed prior approval as a significant issue.

Details on the Pilot Program

The pilot, dubbed “WISER,” which stands for wasteful and inappropriate service reduction, will explore the use of AI algorithms for advance permission decisions on specific Medicare services, like skin replacements and knee surgeries. The federal government argues these procedures are especially prone to inefficiencies that could be addressed by prior approval.

However, certain services, particularly those that pose significant risks to patients during delays, won’t be subjected to AI evaluation, meaning the scope of the pilot is limited.

The slow adoption of AI tools in Medicare contrasts with trends in the private sector, but some experts believe this pilot could prompt significant changes. It’s noted that requests for coverage will be reviewed by qualified clinicians to ensure care is not inappropriately denied. Advocates emphasize that safeguards should minimize any financial incentives towards denying necessary treatments.

Yet, there are worries about how AI might exacerbate existing problems within the approval process. One researcher pointed out that reliance on algorithms could, paradoxically, lead to more denials of care when it’s most needed. Moreover, there are fears that evaluating outcomes might heavily depend on subjective assessments from contractors.

While proponents believe AI can streamline a cumbersome process, past experiences have shown that automated systems can produce flawed results, raising alarms about the implications for patient care.

Evidence gathered from Cigna revealed alarming statistics about the speed at which claims are reviewed, raising further concerns over the human element in care decisions, despite company statements suggesting otherwise.

Class action lawsuits allege that many AI models within the insurance industry fail to account for unique patient needs, increasing financial burdens on those seeking care. According to a recent survey from the American Medical Association, 61% of physicians fear that AI might lead to an uptick in denial rates, exacerbating challenges faced by patients.

Looking Ahead

This new Medicare pilot brings ongoing issues surrounding prior authorization into sharper focus while raising several new questions. The use of AI in determining care eligibility remains a contentious topic, with fears of automated systems disproportionately targeting expensive treatments for denial.

Legislators continue to grapple with the implications of these initiatives, questioning the validation of the pilot and whether it truly protects patient interests or simply leads to more complicated processes. As discussions evolve, both parties are seeking clarity on addressing these challenges.

Representative Murphy acknowledged the uncertainty around whether the pilot will ultimately save Medicare money or aggravate existing hurdles tied to prior approval. “I’m open to see what happens with this,” he stated, reflecting the cautious optimism that surrounds this initiative.